DescriptionProductAvailABIlity:InStock(deliverywithin2-3businessdays,noextrachargefordrop-shipping).Ordering:ToplaceanorderviacreditcardorPOuseAddtoCartbutton(creatinganaccountisnotrequired).TransfectionReagentfor Calu-6Cells(LungCarcinomaCell,HTB-56)LiposomeformulationenhanceslipidmediatedtransfectionefficiencyOptimizedeasy-to-usetransfectionprotocolprovidedfortransfectionofsiRNA,DNA,mRNA,andmicroRNAKitincludesTransfectionEnhancerreagentandrecommendedtransfectionprotocolDownloadinvitroCalu-6transfectionprotocol:[PDF]Download Calu-6CRISPR/Cas9transfectionprotocol:[PDF]DownloadPowerPointpresentationforCalu-6cellstransfectionkit:[PPT]DevelopedandmanufacturedbyAltogenBiosystemsTransfectionEfficiency:Reagentexhibitsatleast90%transfectionefficiencyofsiRNAdelivery.TransfectionefficiencywasdeterminedbyqRT-PCR.TransfectionProtocolandMSDS:DownloadAltogenBiosystemsCalu-6TransfectionProtocol:[PDF]DownloadMSDS:[PDF]Calu-6 CellLine:LungcancerisconsideredtheleADIngcauseofcancerdeathworldwideamongbothwomenandmen,mainlyoccurringinolderpeople,withanaveragepatientageof70yearsandlessthan2%ofalldiagnosedpatientsbeingyoungerthan45,pertheAmericanCancerSociety(ACS).Moreover,itisconsideredthemostpreventablecancer,affectingsmokers15to30timesmoreoftenthanpeoplewhodonotsmoke.TheCalu-6epithelialcelllinewasderivedfromtissueofa61-year-oldCaucasianfemalepatientwithanaplasticcarcinoma(lungcancer).Anaplasticcarcinomaisaconditioninwhichcellsrapidlyproliferate,butlosetheiroriginaldifferentiation,leadingtohighmalignancy.ThemodalchromosomenumberintheCalu-6celllineis59,andthesecellsarehighlyutilizedininvestigativeresearch.Calu-6cellshavebeenusedtobetterunderstandtherelationshipbetweenantimycinA(AMA)andlungcancercells.Ithasbeensuggestedinstudiesthatchangesofreactiveoxygenspecies(ROS)andglutathione(GSH)affectapoptosisinAMA-treatedCalu-6cells.Also,usingAMAasamitochondrialelectrontransportinhibitordecreasedthegrowthofCalu-6cellsbyinducingaG1arrestofthecellcycleandapoptosis.Tiron,aROSscavenger,protectshumanlungcancerCalu-6cellsagainstantimycinA-inducedcelldeath.TheCalu-6celllinehasalsobeenemployedinresearchofthemechanismunderlyingpressuretransductionoftherenin-angiotensinsystem.AltogenBiosystemsprovidespre-optimizedtransfectionreagentkitsfortheCalu-6anaplasticlungcancercelllinethatyieldaround90%transfectionefficiency,asperqRT-PCR.Data:Figure1.GAPDmRNAlevelswerequantifiedusingreal-timeRT-PCRintheCalu-6cellstransfectedwithsiRNAstargetingGAPDornon-silencingsiRNA.Forty-eighthourspost-transfection,thecellswereharvestedandanalyzedbyreal-timeRT-PCRforGAPDHmRNAexpressionlevels.Datawerenormalizedagainstthe18SrRNAsignal.Controlsampleswereeithermock-transfectedoruntreated.Valuesarenormalizedtountreatedsample.Dataaremeans±SD(n=3).Figure2.ProteinexpressionofGAPDHinCalu-6cells.DNAplasmidexpressingGAPDHorsiRNAtargetingGAPDHweretransfectedintoCalu-6cellsfollowingAltogenBiosystemstransfectionprotocol.At72hourspost-transfectionthecellswereanalyzedbyWesternBlotforproteinexpressionlevels(normalizedbytotalprotein,10µgoftotalproteinloadedpereachwell).Untreatedcellsusedasanegativecontrol.SelectedCalu6 transfectionreagentcitationreferences:ClinLungCancer.2015Nov;16(6):e121-9.miRProfilingIdentifiesCyclin-DependentKinase6DownregulationasaPotentialMechanismofAcquiredCisplatinResistanceinNon-Small-CellLungCarcinoma.Baretal[PDF]CancerResearch.201171(15):5144-53.InhibitionofmiR-193aexpressionby…Iliopoulosetal[PDF]RequestaQuoteforCalu-6TransfectionKitAltogenBiosystems:AltogenBiosystemsmanufacturerspreoptimizedtransfectionkitsforcancerresearch.Reagentsandtransfectionprotocolsareoptimizedforindividualcancercelllines.AltogenBiosystemsdevelopedtwotypesofinvivodeliverykitsforanimalresearch:Tissue-targetedreagents(deliveryintoliver,pancreas,andkidneytissues),andinvivobiodistributionreagents(PEG-Liposome,Nanoparticle,Lipid,andPolymer-basedkits).Optimizedtransfectionprotocolsprovideefficientintracellulardeliveryofproteins,DNA,andRNAmoleculesinvitroandinvivo.Readmore abouttransfectiontechnologyatAltogen’sTransfectionResource.AltogenResearchServices:AltogenLabsprovidesGLP-compliantcontractresearchstudiesforpre-clinicalresearch,INDapplications,anddrugdevelopment.OurBIOLOGyCROservices include:Xenograftservices(over60in-housevalidatedxenograftmodels),developmentofstablecelllines,ELISAassaydevelopment,cell-basedandtissuetargetedRNAistudies,safetypharm/toxassays,andotherstudies(visitAltogenLabs.com).VolumeOptions:0.5ml(Catalog#1727)1.5ml(Catalog#1728)1.5mlCRISPR(Catalog#2125)8.0ml(Catalog#7027)
Altogen Biosystems全国代理部分产品列表:
货号
|
产品
|
规格
|
价格(美元)
|
5030
|
|
|
|
1703
|
A204 Transfection Reagent (Rhabdomyosarcoma)
|
0.5ml
|
170
|
1704
|
A204 Transfection Reagent (Rhabdomyosarcoma)
|
1.5ml
|
348
窗体顶端
窗体底端
|
2101
|
A204 Transfection Reagent (Rhabdomyosarcoma)
|
1.5ml CRISPR
|
548
窗体顶端
窗体底端
|
7018
|
A204 Transfection Reagent (Rhabdomyosarcoma)
|
8.0ml
|
1044
窗体顶端
窗体底端
|
1167
|
A375 Cells Transfection Reagent (CRL-1619)
|
0.5ml
|
195
|
1168
|
A375 Cells Transfection Reagent (CRL-1620)
|
1.5ml
|
427
|
2102
|
A375 Cells Transfection Reagent (CRL-1621)
|
1.5ml CRISPR
|
627
|
1169
|
A375 Cells Transfection Reagent (CRL-1622)
|
8.0ml
|
1281
|
5030
|
Nanoparticle In Vivo Transfection Reagent
|
0.5 ml - 10 injections
|
445
|
5010
|
LIPID In Vivo Transfection Reagent
|
0.5 ml - 10 injections
|
405
|
5040
|
PEG-Liposome In Vivo Transfection Reagent
|
0.5 ml - 10 injections
|
465
|
5020
|
POLYMER In Vivo Transfection Reagent
|
0.5 ml - 10 injections
|
425
|
5050
|
Pancreas In Vivo Transfection Kit
|
0.5 ml - 10 injections
|
495
|
5060
|
Liver In Vivo Transfection Kit
|
0.5 ml - 10 injections
|
495
|
5070
|
Kidney In Vivo Transfection Kit
|
0.5 ml - 10 injections
|
495
|
1721
|
BMS2 Transfection Reagent (Bone Marrow Cells)
|
0.5 ml
|
231
|
6345
|
C6 Transfection Reagent (Glioma Cells, CCL-107)
|
0.5 ml
|
199
|
6803
|
DLD-1 Transfection Reagent (Colon Cancer, CCL-221)
|
0.5 ml
|
201
|
1775
|
HUH-7 Transfection Reagent (Liver Cancer Cells)
|
0.5 ml
|
179
|